Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women
Launched by WOMEN'S HOSPITAL SCHOOL OF MEDICINE ZHEJIANG UNIVERSITY · May 12, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment approach for young women who have early-stage endometrial cancer or endometrial hyperplasia and want to preserve their ability to have children. The researchers want to find out if a specific drug, called the membrane-inhibiting formula, taken with oral progestins, can help clear these conditions more quickly and what side effects might occur. They will also look at how effective this treatment is, any side effects that participants may experience, the chances of the condition coming back, and how long it takes to become pregnant after treatment.
To join the trial, women aged 18 to 45 who have been diagnosed with certain types of early-stage endometrial cancer or hyperplasia can apply. Participants will take the study medication daily and visit the clinic every three months for check-ups and tests. They'll also keep a diary to track their health and examination results. It's important to know that women who have certain health conditions or who do not wish to preserve their fertility will not be eligible for the study.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1.18-45 years old with a strong desire to preserve fertility; 2. pathologically diagnosed with primary grade1 or grade2 endometrioid endometrial carcinoma and hyperplasia 3.no signs of suspicious myometrial invasion by enhanced magnetic resonance imaging (MRI) 4. no signs of suspicious extrauterine metastasis by enhanced computed tomography and CT scan of the Lungs
- Exclusion Criteria:
- • 1.have contraindication for pregnancy. 2.no fertility requiremen 3.have myometrial invasion or extrauterine metastasis 4.pathologically diagnosed with primary grade3 endometrioid endometrial carcinoma or non-endometrioid endometrial carcinoma 5.Any disease or symptom that may affect the implementation of the study or the interpretation of the results
About Women's Hospital School Of Medicine Zhejiang University
The Women’s Hospital School of Medicine at Zhejiang University is a leading academic institution dedicated to advancing women's health through innovative research and clinical excellence. With a strong focus on obstetrics, gynecology, and reproductive health, the institution conducts cutting-edge clinical trials aimed at improving patient outcomes and enhancing the understanding of women's health issues. Committed to fostering collaboration between researchers, healthcare professionals, and patients, the Women's Hospital School of Medicine plays a pivotal role in translating scientific discoveries into effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Trial Officials
Yang Li, Doctor
Principal Investigator
Women's Hospital School Of Medicine Zhejiang University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported